## Correct Answer: B. Serous cystadenocarcinoma Serous cystadenocarcinoma is the most common epithelial ovarian malignancy in India and globally, accounting for ~40% of ovarian cancers. The clinical triad presented—gross cystic appearance (cystadenocarcinoma), **CA-125 elevation**, and abdominal heaviness—is pathognomonic for serous tumors. CA-125 is a glycoprotein antigen produced by serous epithelium and is markedly elevated in serous cystadenocarcinomas (often >1000 U/mL), making it the most sensitive tumor marker for this histotype. The gross morphology of a serous cystadenocarcinoma typically shows a large, multiloculated cyst with solid areas, papillary projections, and hemorrhage—consistent with "cystadenocarcinoma" description. Serous tumors arise from müllerian epithelium lining the ovary and frequently present in postmenopausal women with advanced-stage disease (Stage III–IV in 70% of cases). The heaviness in the abdomen reflects the large mass effect and peritoneal involvement common at presentation. Per DC Dutta and Indian gynecology practice, serous cystadenocarcinoma is the DOC diagnosis when CA-125 is positive in an ovarian cystic mass. ## Why the other options are wrong **A. Dysgerminoma** — Dysgerminoma is a germ cell tumor (not epithelial) that typically presents in young women (teens to 30s), not postmenopausal patients. While dysgerminomas do produce tumor markers, they are **AFP and β-hCG positive**, NOT CA-125. CA-125 elevation strongly excludes germ cell tumors. Dysgerminomas also present as solid masses, not cystic lesions. **C. Mucinous carcinoma** — Mucinous cystadenocarcinoma, though cystic, is **CA-19-9 and CEA positive**, not CA-125 positive. CA-125 is rarely elevated in mucinous tumors. Additionally, mucinous carcinomas are less common than serous types (~10% of epithelial ovarian cancers) and typically present at earlier stages. The gross appearance of mucinous tumors is more uniformly gelatinous, not the papillary-solid pattern typical of serous carcinoma. **D. Yolk sac tumor** — Yolk sac tumor (endodermal sinus tumor) is a germ cell malignancy of young girls and adolescents, not postmenopausal women. It is **AFP positive** (often markedly elevated), not CA-125. Yolk sac tumors present as solid masses with hemorrhage and necrosis, not cystic lesions. The clinical presentation and tumor marker profile are entirely different from the case described. ## High-Yield Facts - **Serous cystadenocarcinoma** is the most common epithelial ovarian cancer (~40% of cases) and accounts for the majority of CA-125–positive ovarian malignancies. - **CA-125 >1000 U/mL** in a cystic ovarian mass is highly specific for serous cystadenocarcinoma; other epithelial tumors (mucinous, clear cell) do not elevate CA-125 to this degree. - **Serous tumors arise from müllerian epithelium** and show papillary projections and solid areas on gross examination, distinguishing them from purely mucinous lesions. - **Dysgerminoma and yolk sac tumor** are germ cell tumors marked by AFP/β-hCG, not CA-125; they occur in young women, not postmenopausal patients. - **Stage III–IV disease at presentation** is common in serous cystadenocarcinoma due to late detection; abdominal heaviness reflects mass effect and peritoneal involvement. ## Mnemonics **SEROUS = CA-125** **S**erous tumors → **CA-125** (and papillary morphology). **M**ucinous → CA-19-9/CEA. **G**erm cell → AFP/β-hCG. Use this to instantly link tumor histotype to marker. **CYSTIC + CA-125 = SEROUS** When you see a cystic ovarian mass with CA-125 elevation, think **serous cystadenocarcinoma** first. Mucinous is gelatinous; germ cell tumors are solid. ## NBE Trap NBE pairs "cystic ovarian mass" with "CA-125" to lure students into choosing mucinous carcinoma (which is also cystic). The discriminator is the **CA-125 positivity**—mucinous tumors are CA-19-9/CEA positive, not CA-125. Serous is the only epithelial type that reliably elevates CA-125. ## Clinical Pearl In Indian clinical practice, any postmenopausal woman presenting with abdominal heaviness and a cystic ovarian mass should have CA-125 measured; if elevated, serous cystadenocarcinoma is the presumptive diagnosis until proven otherwise. Early referral to gynecologic oncology for staging (CT abdomen/pelvis, diagnostic laparoscopy) and optimal cytoreductive surgery is critical, as serous tumors are chemosensitive but often present at advanced stage. _Reference: DC Dutta's Textbook of Gynaecology (6th ed.), Ch. 18 (Ovarian Tumours); Robbins & Cotran Pathologic Basis of Disease, Ch. 22 (Female Genital System)_
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.